India, June 14 -- Eli Lilly and Co. (LLY) announced positive results from the Phase 3 BRUIN CLL-322 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, in combination with venetoclax and rituximab versus venetoclax and rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The study met its primary endpoint of independent review committee (IRC)-assessed progression-free survival (PFS). Results showed that adding pirtobrutinib to the two-year venetoclax plus rituximab regimen reduced the risk of disease progression or death by 45%.
Overall survival (OS), a key secondary endpoint, was not yet mature at the time of ...